Maintenance of Benefit With Atomoxetine Hydrochloride in Adolescents With ADHD

Maintenance of Benefit After 8-Week and 52-Week Treatment With Atomoxetine Hydrochloride in Adolescents With ADHD

The purpose of this study is to assess the efficacy, safety and tolerability of atomoxetine administered once daily in the treatment of adolescents with ADHD after 8 weeks and after 52 weeks

Inclusion Criteria:

• Patients must have ADHD.
• Must be 13-16 years of age.
• Must be able to swallow capsules.
• Expected to achieve score of 70 or more on IQ test
• Willing and reliable to keep appts. for clinic visits and test

Exclusion Criteria:

• Treatment within last 30 days with a drug that has not received regulatory approval for any indication.
• Patients who weigh less than 40 kg or greater than 70 kg.
• Patients with documented history of Bipolar I or II disorder, or psychosis
• Patients with documented history of autism, asperger's syndrome or pervasive developmental disorder